Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients were included if they met all of the following criteria:
Patients enrolled in the Kesimpta Go Program
Patients with documented informed consent from enrollment in the Kesimpta Go Program
Patients who started treatment with ofatumumab
You may not be if
Patients were excluded if they met any of the criteria below:
Patients with no demographic information
Patients who could not be linked across the data sources required for analysis (Kesimpta Go Program Enrollment Form, Pharmacy Claims Forms, Kesimpta Go Program Database)
Patients with 3+ treatment interruptions (patient was "on hold" - i.e., not currently receiving the treatment in the patient support program)
Clareo Health | A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
